Meeting
2023 ASCO Annual Meeting
Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the National Cancer Database (NCDB).
Authors
Maroun Bou Zerdan
SUNY Upstate Medical University, Syracuse, NY
Maroun Bou Zerdan , Roger Wong , Hanan Goldberg , Alina Basnet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4552)
DOI
10.1200/JCO.2023.41.16_suppl.4552
Abstract #
4552
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal timing of delayed cytoreductive nephrectomy in metastatic renal cell carcinoma during the immunotherapy era.
First Author: Insija Ilyas Selene
Poster
2023 ASCO Annual Meeting
Role of immunotherapy in stage IV non-small cell lung cancer with liver metastasis: A NCDB analysis.
First Author: Takefumi Komiya
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani